Tobias Mütze

Tobias Mütze

Auto-generated profile, based on publicly available information

Tobias Mütze

Statistical Methodology Novartis Pharma AG Basel Switzerland

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2021 in Statistics in Medicine
Verified
Journal Article
Open access
PDF file
EBEdgar Brunner
Edgar Brunner
MVMarc Vandemeulebroecke
Marc Vandemeulebroecke
TMTobias Mütze
Tobias Mütze
The win ratio, a recently proposed measure for comparing the benefit of two treatment groups, allows ties in the data but ignores ties in the inference. In this article, we highlight some difficulties that this can lead to, and we propose to focus on the win odds instead, a modification of the win ratio which takes ties into account. We construct hypothesis tests and confidence intervals for the win odds, and we investigate their properties through simulations and in a case study. We conclude that the win odds should be preferred over the win ratio.

27 June 2022 in Pharmaceutical Statistics
Verified
Journal Article
Closed access
GDGaohong Dong
Gaohong Dong
BHBo Huang
Bo Huang
JVJohan Verbeeck
Johan Verbeeck
YCYing Cui
Ying Cui
JSJames Song
James Song
JKJohn Edward Kolassa
John Edward Kolassa

5 March 2025 in Pharmaceutical Statistics
Verified
Journal Article
Closed access
JBJames Bell
James Bell
TDThomas Drury
Thomas Drury
TMTobias Mütze
Tobias Mütze
CPChristian Pipper
Christian Pipper
LGLorenzo Guizzaro
Lorenzo Guizzaro
DWDavid Wright
David Wright

17 October 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
TTTobias Tichelbäcker
Tobias Tichelbäcker
LBLeonard Bergau
Leonard Bergau
MPMiriam Puls
Miriam Puls
TFTim Friede
Tim Friede
TMTobias Mütze
Tobias Mütze
SSSamuel Sossalla
Samuel Sossalla
Permanent pacemaker implantation (PPI) following TAVR is a frequent post interventional complication and its management remains controversial. We sought to elucidate the electrophysiological, procedural, and clinical baseline parameters that are associated with and perhaps predict the need for PPI after TAVR in a heterogeneous-valve-type real-world cohort. Overall, 494 patients receiving TAVR at our center from April 2009 to August 2015 were screened. ECG analyses and clinical parameters were collected prospectively. Overall, 401 patients in this all-comers real-world TAVR cohort with a PPI rate of 16% were included. The mean age was 82 years, and the mean duration to PPI was 5.5 days. A large proportion of Edwards SAPIEN valves (81%), DirectFlow, CoreValve, and Portico were implanted. The main indications for PPI were atrioventricular (AV) block III, AV-block Mobitz type II, bradycardic atrial fibrillation and persistent sinus bradycardia. Between groups with and without PPI, significant differences were noted in the prevalence of post TAVR balloon dilatation, resting heart rate, QRS interval, PR interval with a cut-off of >178 ms, left anterior fascicular block and RBBB in univariate analyses. In the subsequent multiple regression analysis, post TAVR balloon dilatation and a PR interval with a cut-off of >178 ms were significant predictors of PPI. This real-world cohort differs from others in its size and heterogeneous valve selection, and indicates for the first time that patients with post balloon dilatation or prolonged PR interval are at a higher risk for pacemaker dependency after TAVR.

4 August 2021 in Statistics in Biopharmaceutical Research
Verified
Journal Article
Closed access
AFArno Fritsch
Arno Fritsch
PSPatrick Schlömer
Patrick Schlömer
FMFranco Mendolia
Franco Mendolia
TMTobias Mütze
Tobias Mütze
AJAntje Jahn-Eimermacher
Antje Jahn-Eimermacher
OCon behalf of the Recurrent Event Qualification Opinion Consortium
on behalf of the Recurrent Event Qualification Opinion Consortium
In clinical trials investigating treatments for chronic heart failure (CHF), a standard primary endpoint is the time to the first composite of hospitalization for heart failure or cardiovascular death (CVD). Since many patients experience several hospitalizations, there is interest in including recurrent hospitalizations into the primary endpoint to better capture disease burden. Several analysis methods have been proposed for recurrent event endpoints, mostly for the situation without a terminal event such as CVD. Only some methods explicitly account for terminal events, for example, the joint frailty model. We compare the power and type I error rate of recurrent event methods with those of time-to-first event methods in the presence of terminal events. A special focus is the situation where treatment affects the risk of CVD. Our investigations are based on a simulation study, for which the scenarios are motivated by CHF trials, and based on bootstraping data from the Val-HeFT and PARADIGM-HF trials. We find that recurrent event methods can in many situations increase power considerably. But this is not always the case, for example, when there is high probability of treatment discontinuation after the first hospitalization. Also, for both recurrent and time-to-first event methods, the type I error rate can be inflated in case of a detrimental treatment effect on CVD. Based on the simulation results we give recommendations on the choice of endpoint and analysis method for CHF trials.

16 November 2016 in Statistics in Medicine
Verified
Journal Article
Closed access
PDF file
TMTobias Mütze
Tobias Mütze
FKFrank Konietschke
Frank Konietschke
AMAxel Munk
Axel Munk
TFTim Friede
Tim Friede